Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN1500 PoC in HoFH
NCT02265952Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of evinacumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Regeneron Pharmaceuticals. Started Feb 2015; status: completed.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT02265952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265952.